A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
NCT ID: NCT00373113
Last Updated: 2012-06-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
482 participants
INTERVENTIONAL
2006-11-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
NCT00435409
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
NCT00246571
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
NCT00471276
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
NCT00618124
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00482755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Capecitabine
1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
B
37.5 mg daily, continuous dosing
Sunitinib malate
37.5 mg daily, continuous dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capecitabine
1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Sunitinib malate
37.5 mg daily, continuous dosing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* prior treatment with an anthracycline and a taxane either concurrently or sequentially in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than 1 chemotherapy regimen in the advanced setting
Exclusion Criteria
* Any prior regimen with capecitabine
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Córdoba, Córdoba Province, Argentina
Pfizer Investigational Site
Bahía Blanca, Prov. de Buenos Aires, Argentina
Pfizer Investigational Site
Viedma, Río Negro Province, Argentina
Pfizer Investigational Site
Rosario, Santa Fe Province, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
San Miguel de Tucumán, , Argentina
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Sofia, Bulgaria, Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Stara Zagora, , Bulgaria
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Temuco, Región de la Araucanía, Chile
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Bogotá, Cundinamarca, Colombia
Pfizer Investigational Site
Bayonne, , France
Pfizer Investigational Site
Besançon, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Neuilly-sur-Seine, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Jena, , Germany
Pfizer Investigational Site
Kiel, , Germany
Pfizer Investigational Site
Leer, , Germany
Pfizer Investigational Site
Lübeck, , Germany
Pfizer Investigational Site
Magdeburg, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
Meiningen, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Offenburg, , Germany
Pfizer Investigational Site
Tübingen, , Germany
Pfizer Investigational Site
Hong Kong, , Hong Kong
Pfizer Investigational Site
Kowloon, , Hong Kong
Pfizer Investigational Site
Tuenmen, , Hong Kong
Pfizer Investigational Site
Wan Chai, , Hong Kong
Pfizer Investigational Site
Navrangpura / Ahmedabad, Gujarat, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Ludhiana, Punjab, India
Pfizer Investigational Site
Jaipur, Rajasthan, India
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Reggio Emilia, , Italy
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
Pfizer Investigational Site
Matsuyama, Ehime, Japan
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
Pfizer Investigational Site
Kitakyushu, Fukuoka, Japan
Pfizer Investigational Site
Osaka, Osaka, Japan
Pfizer Investigational Site
Suita, Osaka, Japan
Pfizer Investigational Site
Kita-adachi-gun, Saitama, Japan
Pfizer Investigational Site
Bunkyo-ku, Tokyo, Japan
Pfizer Investigational Site
Chuo-Ku, Tokyo, Japan
Pfizer Investigational Site
Chihuahua City, Chihuahua, Mexico
Pfizer Investigational Site
Acapulco de Juárez, Guerrero, Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Morelia, Michoacán, Mexico
Pfizer Investigational Site
Puebla City, Puebla, Mexico
Pfizer Investigational Site
Ciudad Obregón, Sonora, Mexico
Pfizer Investigational Site
Toluca, State of Mexico, Mexico
Pfizer Investigational Site
Lima, Lima Province, Peru
Pfizer Investigational Site
Lima, , Peru
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
San Juan City, , Philippines
Pfizer Investigational Site
Singapore, Singapore, Singapore
Pfizer Investigational Site
Singapore, Singapore, Singapore
Pfizer Investigational Site
Parktown, , South Africa
Pfizer Investigational Site
Sandton, , South Africa
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Incheon, , South Korea
Pfizer Investigational Site
Pusan, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Mataró, Barcelona, Spain
Pfizer Investigational Site
Sabadell, Barcelona, Spain
Pfizer Investigational Site
Santander, Cantabria, Spain
Pfizer Investigational Site
Córdoba, Cordoba, Spain
Pfizer Investigational Site
Girona, Gerona, Spain
Pfizer Investigational Site
Jaén, Jaen, Spain
Pfizer Investigational Site
A Coruña, La Coruña, Spain
Pfizer Investigational Site
Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
Pfizer Investigational Site
Alcorcón, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Málaga, Malaga, Spain
Pfizer Investigational Site
Salamanca, Salamanca, Spain
Pfizer Investigational Site
Bilbao, Vizcaya, Spain
Pfizer Investigational Site
Changhua, , Taiwan
Pfizer Investigational Site
Kaohsiung City, , Taiwan
Pfizer Investigational Site
Tainan City, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taoyuan District, , Taiwan
Pfizer Investigational Site
Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Cardiff, South Wales, United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Nottingham, , United Kingdom
Pfizer Investigational Site
Somerset, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6181107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.